Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 6/20 | 0.53 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.49 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.43 |
| ▸ | PDE4A | P27815 | 3/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15144072 | 0.93 | BRD4 (0.49) | SLC6A9KAT2BBAZ2BLMNASYK | |
| SCHEMBL2824807 | 0.88 | SLC6A9 (0.51) | SLC6A9LMNAPDE4DPDE4APDE4B | |
| SCHEMBL1811462 | 0.88 | SLC6A9 (0.51) | SLC6A9LMNAPDE4DPDE4APDE4B | |
| SCHEMBL2826409 | 0.87 | SLC6A9 (0.52) | SLC6A9LMNASYKPDE4DPDE4A | |
| SCHEMBL5041669 | 0.86 | KAT2B (0.52) | SLC6A9KAT2BBAZ2BSYKPDE4D | |
| SCHEMBL5037704 | 0.83 | KAT2B (0.46) | SLC6A9KAT2BBAZ2BSYKPDE4D | |
| SCHEMBL5038123 | 0.80 | SLC6A9 (0.45) | SLC6A9LMNAAPEX1BRD4 | |
| SCHEMBL25314851 | 0.79 | KAT2B (0.50) | KAT2BBAZ2BSYKPDE4DPDE4A | |
| SCHEMBL30507985 | 0.79 | KAT2B (0.50) | KAT2BBAZ2BSYKPDE4DPDE4A | |
| SCHEMBL1813772 | 0.77 | LMNA (0.50) | SLC6A9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605163-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | JOLIDON SYNESE | 2008-05-22 | — | — | US | disclosed |
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1656361-B1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |
| EP-1656361-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005014563-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | SLC6A9 82/4885KAT2B 1204/4885BAZ2B 1545/4885 |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | SLC1A2, SLC18A2, SLC6A7 | SLC6A9 82/4885KAT2B 1204/4885BAZ2B 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.